Limited Approval For A New Aids Drug

Eager to get a second AIDS drug on the market, the Food & Drug Administration granted approval on Oct. 9 to Bristol-Myers Squibb's DDI--even though clinical trials with the drug are still in progress. The FDA, however, is still being cautious. It has limited the approved use of DDI to AIDS patients who are unable to take, or who have not been helped by, Burroughs Wellcome's AZT, the only other approved AIDS drug. DDI will cost less than $2,000 per year at the most common dose, compared with AZT's typical cost of $2,200 and up.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.